Shield-1 is a synthetic ligand for destabilizing domain systems based on engineered FKBP-derived protein tags. It binds the destabilizing domain and stabilizes tagged fusion proteins, making it an important chemical biology tool for conditional protein control. Shield-1 is not a conventional PROTAC target warhead, but it is highly relevant to protein stability and degradation research because it enables ligand-regulated protection of engineered proteins from cellular degradation. In experimental workflows, Shield-1 can be used to control protein abundance, validate degrader phenotypes, study reversible protein stabilization, and compare induced stabilization with induced degradation systems. Its value lies in temporal control of tagged protein expression, target validation, protein homeostasis studies, engineered cellular models, and chemical-genetic approaches for dissecting protein function in living systems.
Structure of 914805-33-7
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Target: This ligand targets engineered FKBP12(F36V) destabilizing domains in biochemical or cellular target-engagement studies.
Mechanism of Action: Shield-1 is best established as a ligand for engineered FKBP12(F36V) destabilizing domains rather than a conventional endogenous PROTAC target ligand. In degrader-related experimental design, this binding interaction can be exploited to control stability of fusion proteins or to build chemically induced proximity systems when connected to an appropriate linker and recruitment module. If adapted into a bifunctional degrader architecture, the ligand portion would recognize the engineered FKBP12 tag while the second ligand recruits an E3 ligase, enabling proximity-dependent ubiquitination and proteasomal degradation of the tagged protein.
Applications• PROTAC E3 Recruitment Tool: Shield-1 can be used in PROTAC research as a chemically controllable component to modulate recruitment of an E3 ligase system. By enabling tunable formation of ternary complexes, Shield-1 supports studies of how ligase engagement kinetics and affinity influence ubiquitination efficiency and subsequent target protein degradation.
• Inducible Degradation Control: Shield-1–dependent PROTAC designs facilitate on-demand targeted protein degradation, allowing researchers to vary degrader activity over time. This enables mechanistic experiments to quantify degradation onset, dose–response relationships, and recovery after washout, supporting rigorous mapping of degradation dynamics in cellular systems.
• Ternary Complex Optimization: In PROTAC development workflows, Shield-1–enabled ligase recruitment can help dissect ternary complex stability requirements. Researchers can systematically compare degradation potency under different induction conditions, informing structure–activity relationships that govern productive ubiquitination and reducing off-target proteolysis.
• Mechanistic Ubiquitination Studies: Shield-1–driven PROTAC platforms are suitable for probing ubiquitin pathway engagement. By controlling when the degrader becomes active, experiments can measure ubiquitination intermediates, dependence on specific E2/E3 factors, and the contribution of proteasomal processing to overall target turnover.
• Target Pathway Perturbation: Shield-1–controlled PROTAC activity supports targeted perturbation of signaling networks by selectively degrading chosen proteins. This approach is valuable for testing causal roles of protein abundance, examining downstream transcriptional or phenotypic effects, and distinguishing degradation-dependent mechanisms from occupancy-only binding.
Shield-1 is a FKBP-family ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.
Structure: The structure of Shield-1 is characterized by carboxylic acid or carboxylate handle; primary or secondary amine/basic nitrogen centers; macrocyclic or peptidomimetic scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.
Reactivity: The acid handle supports amide coupling with amino-PEG, alkyl-diamine, piperazine, or aminoalkyl E3-ligase ligands. For FKBP-directed chemical biology, it may be connected to degradation or dimerization modules through flexible PEG/alkyl or amide-containing linkers, subject to FKBP-binding SAR. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.